VENTURA COUNTY
HEALTH CARE PLAN

Prior Authorization Drug Guidelines

THYMOGLOBULIN (anti-thymocyte globulin)

Effective Date: 10/20/214
Date Developed: 10/14/214
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20, 2/2/21, 8/3/21, 2/1/22

Description: Thymoglobulin is a purified, pasteurized gamma immune globulin obtained by immunizing rabbits with human thymocytes resulting in several clones of antilymphocytes capable of inhibiting the proliferative responses to several mitogens. It does this by acting on T-cell surface antigens and depleting CD4 lymphocytes

Authorization Criteria: Treatment of acute rejection in renal transplants in conjunction with other immunosuppressants

NOTE: Should only be used by physicians experienced in immunosuppressive therapy in transplantation. Should be used under strict medical supervision in a hospital setting, and patients should be carefully monitored during the infusion.

Dosing:

Renal transplant acute rejection:1.5 mg/kg daily for 7-14 days (infused over a minimum 6 hours for the first infusion and at least 4 hours on subsequent days) reduce dose by one-half if the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3; stopping treatment should be considered if the WBC count falls below 2,000 cells/mm3 or platelets below 50,000 cells/mm3

Renal transplant induction therapy: IV: 1.5 mg/kg/day for 4 to 7 days; the first dose should be administered prior to reperfusion of the donor kidney

NOTE: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

How Supplied: Lyophilized: 25mg/10 mL vial (reconstitute with sterile water)

VENTURA COUNTY
HEALTH CARE PLAN

Major Adverse Reactions: Acute infections; reactivation of latent infectious agents; sepsis; increased risk of malignancy; inflammatory reaction at the infusion site; lymphopenia; thrombocytopenia; Serious immune-mediated reactions, e.g. anaphylaxis or severe cytokine release syndrome (CRS; “cytokine storm”);

REFERENCES

1. Bonnefoy-Bérard N, et al. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. *Transplantation* (1991)**51**:669-673.
2. Bonnefoy-Bérard N, et al. Inhibition of CD25 (IL-2Rα) expression and Tcell proliferation by polyclonal anti-thymocyte globulins. *Immunology* (1992)**77**:61-67.
3. Bourdage J, et al. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. *Transplantation* (1995)**59**:1194-1200.
4. Gaber AO, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. *Transplantation* (1998)**66**:29-37.
5. Hardinger KL, “Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation,” *Pharmacotherapy*, 2006, 26(12):1771-83.
6.
7. Balaha M, Al-Otaibi T, Gheith OA, et al. Thymoglobulin-resistant t-cell-mediated acute rejection in a pregnant renal transplant recipient: case report and review of the literature. Exp Clin Transplant. 2019;17(Suppl 1):159-163.
8. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977.
9. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003;76(5):798-802.
10.
    Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation. 2010;90(12):1516-1520.

Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. Transplantation. 2003;75(4):488-489.

VENTURA COUNTY
HEALTH CARE PLAN

Revision History:

Date Approved by P&T Committee: 10/28/14; QAC 11/25/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/2/21
Date Reviewed/Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Added info and references; format changes
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review